MCID: TRN018
MIFTS: 53

Transitional Cell Carcinoma malady

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Transitional Cell Carcinoma

Aliases & Descriptions for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 50 14
Carcinoma, Transitional Cell 42 69
Transitional Cell Neoplasm 12 69
Transitional Cell Carcinoma of Bladder 69
Carcinoma Transitional Cell 52
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2671
MeSH 42 D002295
NCIt 47 C2930 C6783

Summaries for Transitional Cell Carcinoma

Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to papillary transitional carcinoma and linitis plastica. An important gene associated with Transitional Cell Carcinoma is UPK2 (Uroplakin 2), and among its related pathways/superpathways are Cytoskeletal Signaling and Pathways in cancer. The drugs Immunoglobulins and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and ovary, and related phenotypes are homeostasis/metabolism and embryo

Wikipedia : 71 Transitional cell carcinoma (TCC) also urothelial carcinoma (UCC), is a type of cancer that typically... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
id Related Disease Score Top Affiliating Genes
1 papillary transitional carcinoma 32.8 CDH1 KRT20 TP53 UPK3A
2 linitis plastica 29.9 CDH1 TP53
3 sarcomatoid transitional cell carcinoma 12.3
4 prostate transitional cell carcinoma 12.1
5 ureter transitional cell carcinoma 12.1
6 ovary transitional cell carcinoma 12.1
7 invasive bladder transitional cell carcinoma 12.1
8 renal pelvis transitional cell carcinoma 12.1
9 fallopian tube transitional cell carcinoma 12.1
10 non-papillary transitional cell carcinoma of the bladder 12.0
11 transitional cell carcinoma of the corpus uteri 12.0
12 bartholin's gland transitional cell carcinoma 12.0
13 endometrial transitional cell carcinoma 12.0
14 bladder papillary transitional cell neoplasm 12.0
15 urethra transitional cell carcinoma 12.0
16 kidney pelvis sarcomatoid transitional cell carcinoma 12.0
17 urinary tract non-invasive transitional cell neoplasm 11.9
18 infiltrating renal pelvis transitional cell carcinoma 11.9
19 infiltrating ureter transitional cell carcinoma 11.9
20 prostate cancer 11.2
21 bladder urothelial carcinoma 11.2
22 bladder cancer, somatic 11.1
23 urethral cancer 10.9
24 prostate cancer, hereditary, 12 10.9
25 prostate cancer, hereditary, 13 10.9
26 balkan nephropathy 10.9
27 prostate cancer, hereditary, 2 10.9
28 prostate cancer, hereditary, 11 10.9
29 prostate cancer 1 10.9
30 fallopian tube carcinoma 10.9
31 microglandular adenosis 10.4 KRT7 UPK3A
32 pineal region mature teratoma 10.4 EGFR ERBB2
33 wolffian adnexal neoplasm 10.4 EGFR TP53
34 anal carcinoma in situ 10.3 KRT7 TP53 UPK2
35 basaloid squamous cell carcinoma 10.3 CDH1 EGFR ERBB2
36 radiculopathy 10.3 KRT20 KRT7
37 secondary hyperparathyroidism of renal origin 10.3 EGFR TP53 UPK3A
38 combined t cell and b cell immunodeficiency 10.3 CDH1 EGFR ERBB2
39 clear cell adenofibroma 10.3 IFNA2 TP53
40 adult myxoid chondrosarcoma 10.3 KRT20 KRT7
41 sclerosing hemangioma 10.3 CDH1 EGFR ERBB2
42 urethral verrucous carcinoma 10.3 PTGS2 TP53 UPK2
43 nervous system hibernoma 10.3 EGFR ERBB2 KRT7
44 immunodeficiency due to a late component of complement deficiency 10.3 EGFR ERBB2 TP53
45 retinal disease 10.3 CDH1 EGFR ERBB2
46 paraphimosis 10.3 KRT20 KRT7 TP53
47 acquired hemangioma 10.3 ERBB2 PTGS2 TP53
48 papillary adenofibroma 10.3 KRT20 KRT7 TP53
49 basophilic carcinoma 10.3 CDH1 KRT7 TP53
50 nodular cutaneous amyloidosis 10.3 CDH1 KRT7 TP53

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 BRINP1 CDH1 DAPK1 EGFR ERBB2 KRT7
2 embryo MP:0005380 9.86 CDH1 EGFR ERBB2 KRT18 KRT8 PTGS2
3 neoplasm MP:0002006 9.5 ERBB2 MSH2 PSCA PTGS2 TP53 CDH1
4 renal/urinary system MP:0005367 9.17 DAPK1 EGFR KRT7 PTGS2 TP53 UPK2

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
3 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4
Vinblastine Approved Phase 2, Phase 3, Phase 1 865-21-4 13342 241903
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
10
Selenium Approved, Vet_approved Phase 3 7782-49-2
11
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
12
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
13
Valrubicin Approved Phase 3,Phase 2,Phase 1 56124-62-0 41744
14
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 453 6251
15
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
18
Aminolevulinic acid Approved Phase 3 106-60-5 137
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
21
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
22
Ethanol Approved Phase 3 64-17-5 702
23
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
24
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
25
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
26
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
27
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
28
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
29
Cephalexin Approved, Vet_approved Phase 3 15686-71-2 27447
30
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
31
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
34
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
35
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
36
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
37
Fenretinide Investigational Phase 3 65646-68-6
38
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
39
Levulinic acid Experimental Phase 3 123-76-2 11579
40
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
41
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
42 taxane Phase 3,Phase 2
43 Mitogens Phase 3,Phase 2,Phase 1
44 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
45 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
46 Nicotinic Acids Phase 3,Phase 2,Phase 1
47 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
48 Tocopherols Phase 3
49 Tocotrienols Phase 3
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 425)
id Name Status NCT ID Phase
1 An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy Approved for marketing NCT02589717 Phase 4
2 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3
3 Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Unknown status NCT01830231 Phase 2, Phase 3
4 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3
5 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
6 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3
7 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3
8 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3
9 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
10 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
11 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3
12 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3
13 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3
14 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3
15 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3
16 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3
17 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3
18 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3
19 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3
20 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3
21 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
22 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3
23 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3
24 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
25 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
26 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
27 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3
28 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
29 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3
30 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3
31 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3
32 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3
33 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3
34 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
35 A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010] Recruiting NCT02450331 Phase 3
36 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3
37 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Recruiting NCT02853305 Phase 3
38 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3
39 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
40 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Recruiting NCT01993979 Phase 3
41 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
42 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
43 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3
44 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
45 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
46 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3
47 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
48 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Active, not recruiting NCT02818725 Phase 3
49 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3
50 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Genetic Tests for Transitional Cell Carcinoma

Anatomical Context for Transitional Cell Carcinoma

MalaCards organs/tissues related to Transitional Cell Carcinoma:

39
Kidney, Prostate, Ovary, Lymph Node, Endothelial, Lung, Brain

Publications for Transitional Cell Carcinoma

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 1192)
id Title Authors Year
1
Huge Prostatic Utricle with Transitional Cell Carcinoma in an Adult. ( 28065811 )
2017
2
Thrombus-like Tumor of Renal Cell Carcinoma Mimicking Transitional Cell Carcinoma of Kidney: A Case Report. ( 27896135 )
2017
3
Radical Cystectomy and Cutaneous Ureterostomy in 4 Dogs with Trigonal Transitional Cell Carcinoma: Description of Technique and Case Series. ( 27911468 )
2017
4
Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. ( 27878359 )
2017
5
Re: Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. ( 27465469 )
2016
6
Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway. ( 26742010 )
2016
7
Unusual Development of Pulmonary Tumor Embolism from Controlled Liver Metastases of Transitional Cell Carcinoma: An Autopsy Case. ( 27580549 )
2016
8
Characteristics of bladder transitional cell carcinoma with E-cadherin and N-cadherin double-negative expression. ( 27347176 )
2016
9
Transitional Cell Carcinoma in the Pediatric Patient: A Review of the Literature. ( 26802795 )
2016
10
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. ( 27228294 )
2016
11
A pure primary transitional cell carcinoma of the ovary: A rare case report with literature review. ( 27127747 )
2016
12
Transitional cell carcinoma: A rare development in congenital ureteropelvic junction obstruction kidney. ( 26941502 )
2016
13
MicroRNA-497 inhibits the proliferation, migration and invasion of human bladder transitional cell carcinoma cells by targeting E2F3. ( 27430325 )
2016
14
Thyroid metastasis of bladder transitional cell carcinoma. ( 27126668 )
2016
15
Hematospermia and Cloacogenic Transitional Cell Carcinoma: A Twist on Significance and Meaning. ( 26977332 )
2016
16
Long-Term Results and Prognostic Factors of Pulmonary Metastasectomy in Patients with Metastatic Transitional Cell Carcinoma. ( 27148929 )
2016
17
WE-DE-BRA-03: Construction of An Ultrasound Guidance Platform for Image-Guided Radiotherapy with the Intent to Treat Transitional Cell Carcinoma. ( 28047007 )
2016
18
Demonstration of synchrotron x-ray phase contrast imaging computed tomography of infiltrative transitional cell carcinoma of the prostatic urethra in a dog. ( 27014719 )
2016
19
Primary amyloidosis of urinary bladder: Mimicking transitional cell carcinoma bladder? ( 26900233 )
2016
20
Re: A Case of High-Grade Transitional Cell Carcinoma of the Bladder in a Pediatric Patient with Turner Syndrome. ( 27597108 )
2016
21
Transitional cell carcinoma with extension of the renal vein and IVC tumor thrombus: report of three cases and literature review. ( 28031042 )
2016
22
Prognostic Significance of Transitional Cell Carcinoma-Like Morphology of High-Grade Serous Ovarian Carcinoma: A Comparative Study. ( 27575630 )
2016
23
Choroidal Metastasis as an Unusual Initial Presentation of Transitional Cell Carcinoma of the Kidney. ( 27920701 )
2016
24
Diagnostic value of strain elastography for differentiation between renal cell carcinoma and transitional cell carcinoma of kidney. ( 26880174 )
2016
25
Robot-Assisted Laparoscopic Nephroureterectomy for Transitional Cell Carcinoma of a Right Pelvic Kidney. ( 27579441 )
2016
26
Molecular cystoscopy: Micro-RNAs could be a marker for identifying genotypic changes for transitional cell carcinoma of the urinary bladder. ( 27127359 )
2016
27
Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. ( 27453656 )
2016
28
Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. ( 26810191 )
2016
29
Primary Retroperitoneal Transitional Cell Carcinoma - A Rare Clinical Entity. ( 27734432 )
2016
30
Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression. ( 27482329 )
2016
31
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review. ( 27765044 )
2016
32
Intrascotal metastasis of bladder transitional cell carcinoma as initial presentation of the disease. ( 28039727 )
2016
33
Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. ( 27559301 )
2016
34
Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. ( 27539085 )
2016
35
Association of ABO blood types and clinicopathological features of ureteral transitional cell carcinoma in a single-center in China. ( 27461617 )
2016
36
Posterior reversible encephalopathy syndrome mimicking brain metastases in a patient with metastatic transitional cell carcinoma. ( 27726296 )
2016
37
Investigation of the association between mitochondrial DNA and p53 gene mutations in transitional cell carcinoma of the bladder. ( 27698873 )
2016
38
Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin for Kidney Transplant Patients With Locally Advanced Transitional Cell Carcinoma: A Single-center Experience. ( 27569947 )
2016
39
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. ( 27855679 )
2016
40
Novel somatic mutations identified by whole-exome sequencing in muscle-invasive transitional cell carcinoma of the bladder. ( 26893765 )
2016
41
TOLERABILITY AND TUMOR RESPONSE OF A NOVEL LOW-DOSE PALLIATIVE RADIATION THERAPY PROTOCOL IN DOGS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER AND URETHRA. ( 26841125 )
2016
42
Patterns of Recurrence in Upper Tract Transitional Cell Carcinoma: Imaging Surveillance. ( 27382922 )
2016
43
Bladder and vaginal transitional cell carcinoma: A case report. ( 27602160 )
2016
44
Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder. ( 27895724 )
2016
45
Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors. ( 27366313 )
2016
46
Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. ( 26781446 )
2016
47
Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan. ( 26662954 )
2016
48
Erratum to: A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. ( 28038672 )
2016
49
Clinical experience of MRI in two dogs with muscle-invasive transitional cell carcinoma of the urinary bladder. ( 27149892 )
2016
50
Downregulation of UPK1A suppresses proliferation and enhances apoptosis of bladder transitional cell carcinoma cells. ( 25701463 )
2015

Variations for Transitional Cell Carcinoma

Copy number variations for Transitional Cell Carcinoma from CNVD:

7 (show top 50) (show all 92)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification ORAOV1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification C11orf76 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification FAM19A2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TM4SF3 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss SDFR1 Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss SDCCAG33 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss ZADH2 Urothelial cell carcinoma

Expression for Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for Transitional Cell Carcinoma

GO Terms for Transitional Cell Carcinoma

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 CDH1 ENO2 KRT18 KRT7 KRT8 PSCA
2 intermediate filament GO:0005882 9.26 KRT18 KRT20 KRT7 KRT8
3 apical plasma membrane GO:0016324 9.1 EGFR ERBB2 UPK1A UPK1B UPK2 UPK3A

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.56 KRT18 KRT20 KRT7 KRT8
2 cell surface receptor signaling pathway GO:0007166 9.55 EGFR ERBB2 IFNA2 UPK1A UPK1B
3 negative regulation of ERBB signaling pathway GO:1901185 9.4 EGFR ERBB2
4 determination of adult lifespan GO:0008340 9.37 MSH2 TP53
5 hepatocyte apoptotic process GO:0097284 9.32 KRT18 KRT8
6 cornification GO:0070268 9.26 KRT18 KRT20 KRT7 KRT8
7 epithelial cell differentiation GO:0030855 8.92 UPK1A UPK1B UPK2 UPK3A

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.56 KRT18 KRT7 KRT8 UPK1B
2 protein phosphatase binding GO:0019903 9.13 EGFR ERBB2 TP53
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.62 EGFR ERBB2
4 protein binding GO:0005515 10.09 BRINP1 CDH1 DAPK1 EGFR ENO2 ERBB2

Sources for Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....